Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors

Giulia Mesiano, Maja Todorovic, Loretta Gammaitoni, Valeria Leuci, Lidia Giraudo Diego, Fabrizio Carnevale-Schianca, Franca Fagioli, Wanda Piacibello, Massimo Aglietta, Dario Sangiolo

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Introduction: Cytokine-induced killer (CIK) cells are heterogeneous ex vivo-expanded T lymphocytes with mixed T-NK phenotype and endowed with a wide MHC-unrestricted antitumor activity. CIK cells can be expanded from peripheral blood mononuclear cells (PBMC) cultured with the timed addition of IFN-γ, Ab anti-CD3 and IL2. A consistent subset of mature CIK cells presents a CD3 +CD56+ phenotype. The CD3+CD56+ cellular subset is the main responsible for the tumor-killing activity, mostly mediated by the interaction of NKG2D receptor with MHC-unrestricted ligands (MIC A/B; ULBPs) on tumor cells. Areas covered: In the present work, we described the biologic characteristics of CIK cells, focusing on those aspects that may favor their clinical translation. We reviewed preclinical data and analyzed reports from clinical trials. A specific paragraph is dedicated to future research perspectives in the field. Expert opinion: CIK cells represent a realistic new option in the field of cancer immunotherapy. Crucial issues, favoring their clinical translation, are the easy availability of large amounts of expanded CIK cells and their MHC-unrestricted tumor killing, potentially effective against many tumor types. Intriguing future perspectives and open challenges are the investigation of synergisms with other immunotherapy approaches, targeted therapies or even conventional chemotherapy.

Original languageEnglish
Pages (from-to)673-684
Number of pages12
JournalExpert Opinion on Biological Therapy
Volume12
Issue number6
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Cytokine-Induced Killer Cells
Adoptive Immunotherapy
Tumors
Cytokines
Neoplasms
Immunotherapy
Therapeutics
NK Cell Lectin-Like Receptor Subfamily K
Phenotype
Chemotherapy
T-cells
Expert Testimony
Interleukin-2
Blood Cells
Blood
Cells
Clinical Trials
Availability
Ligands
T-Lymphocytes

Keywords

  • Adoptive cell therapy
  • CIK cells
  • Immunotherapy
  • Solid tumors

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. / Mesiano, Giulia; Todorovic, Maja; Gammaitoni, Loretta; Leuci, Valeria; Giraudo Diego, Lidia; Carnevale-Schianca, Fabrizio; Fagioli, Franca; Piacibello, Wanda; Aglietta, Massimo; Sangiolo, Dario.

In: Expert Opinion on Biological Therapy, Vol. 12, No. 6, 06.2012, p. 673-684.

Research output: Contribution to journalArticle

@article{32e3a58ee0cf4c2baab568f58fdf529f,
title = "Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors",
abstract = "Introduction: Cytokine-induced killer (CIK) cells are heterogeneous ex vivo-expanded T lymphocytes with mixed T-NK phenotype and endowed with a wide MHC-unrestricted antitumor activity. CIK cells can be expanded from peripheral blood mononuclear cells (PBMC) cultured with the timed addition of IFN-γ, Ab anti-CD3 and IL2. A consistent subset of mature CIK cells presents a CD3 +CD56+ phenotype. The CD3+CD56+ cellular subset is the main responsible for the tumor-killing activity, mostly mediated by the interaction of NKG2D receptor with MHC-unrestricted ligands (MIC A/B; ULBPs) on tumor cells. Areas covered: In the present work, we described the biologic characteristics of CIK cells, focusing on those aspects that may favor their clinical translation. We reviewed preclinical data and analyzed reports from clinical trials. A specific paragraph is dedicated to future research perspectives in the field. Expert opinion: CIK cells represent a realistic new option in the field of cancer immunotherapy. Crucial issues, favoring their clinical translation, are the easy availability of large amounts of expanded CIK cells and their MHC-unrestricted tumor killing, potentially effective against many tumor types. Intriguing future perspectives and open challenges are the investigation of synergisms with other immunotherapy approaches, targeted therapies or even conventional chemotherapy.",
keywords = "Adoptive cell therapy, CIK cells, Immunotherapy, Solid tumors",
author = "Giulia Mesiano and Maja Todorovic and Loretta Gammaitoni and Valeria Leuci and {Giraudo Diego}, Lidia and Fabrizio Carnevale-Schianca and Franca Fagioli and Wanda Piacibello and Massimo Aglietta and Dario Sangiolo",
year = "2012",
month = "6",
doi = "10.1517/14712598.2012.675323",
language = "English",
volume = "12",
pages = "673--684",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors

AU - Mesiano, Giulia

AU - Todorovic, Maja

AU - Gammaitoni, Loretta

AU - Leuci, Valeria

AU - Giraudo Diego, Lidia

AU - Carnevale-Schianca, Fabrizio

AU - Fagioli, Franca

AU - Piacibello, Wanda

AU - Aglietta, Massimo

AU - Sangiolo, Dario

PY - 2012/6

Y1 - 2012/6

N2 - Introduction: Cytokine-induced killer (CIK) cells are heterogeneous ex vivo-expanded T lymphocytes with mixed T-NK phenotype and endowed with a wide MHC-unrestricted antitumor activity. CIK cells can be expanded from peripheral blood mononuclear cells (PBMC) cultured with the timed addition of IFN-γ, Ab anti-CD3 and IL2. A consistent subset of mature CIK cells presents a CD3 +CD56+ phenotype. The CD3+CD56+ cellular subset is the main responsible for the tumor-killing activity, mostly mediated by the interaction of NKG2D receptor with MHC-unrestricted ligands (MIC A/B; ULBPs) on tumor cells. Areas covered: In the present work, we described the biologic characteristics of CIK cells, focusing on those aspects that may favor their clinical translation. We reviewed preclinical data and analyzed reports from clinical trials. A specific paragraph is dedicated to future research perspectives in the field. Expert opinion: CIK cells represent a realistic new option in the field of cancer immunotherapy. Crucial issues, favoring their clinical translation, are the easy availability of large amounts of expanded CIK cells and their MHC-unrestricted tumor killing, potentially effective against many tumor types. Intriguing future perspectives and open challenges are the investigation of synergisms with other immunotherapy approaches, targeted therapies or even conventional chemotherapy.

AB - Introduction: Cytokine-induced killer (CIK) cells are heterogeneous ex vivo-expanded T lymphocytes with mixed T-NK phenotype and endowed with a wide MHC-unrestricted antitumor activity. CIK cells can be expanded from peripheral blood mononuclear cells (PBMC) cultured with the timed addition of IFN-γ, Ab anti-CD3 and IL2. A consistent subset of mature CIK cells presents a CD3 +CD56+ phenotype. The CD3+CD56+ cellular subset is the main responsible for the tumor-killing activity, mostly mediated by the interaction of NKG2D receptor with MHC-unrestricted ligands (MIC A/B; ULBPs) on tumor cells. Areas covered: In the present work, we described the biologic characteristics of CIK cells, focusing on those aspects that may favor their clinical translation. We reviewed preclinical data and analyzed reports from clinical trials. A specific paragraph is dedicated to future research perspectives in the field. Expert opinion: CIK cells represent a realistic new option in the field of cancer immunotherapy. Crucial issues, favoring their clinical translation, are the easy availability of large amounts of expanded CIK cells and their MHC-unrestricted tumor killing, potentially effective against many tumor types. Intriguing future perspectives and open challenges are the investigation of synergisms with other immunotherapy approaches, targeted therapies or even conventional chemotherapy.

KW - Adoptive cell therapy

KW - CIK cells

KW - Immunotherapy

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=84861327182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861327182&partnerID=8YFLogxK

U2 - 10.1517/14712598.2012.675323

DO - 10.1517/14712598.2012.675323

M3 - Article

C2 - 22500889

AN - SCOPUS:84861327182

VL - 12

SP - 673

EP - 684

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 6

ER -